Monte Rosa Therapeutics, Inc.

6.32 USD
+0.02 (+0.32%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Monte Rosa Therapeutics, Inc. stock is up 33.9% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 March’s closed higher than February. 100% of analysts rate it a buy.

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. engages in the development of novel small molecule precision medicines. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers.